Triptorelin at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Triptorelin is a synthetic decapeptide GnRH (gonadotropin-releasing hormone) agonist that is structurally similar to endogenous GnRH but with substitutions that dramatically extend its half-life and receptor binding potency. It is FDA approved under brand names Decapeptyl and Trelstar as long-acting depot formulations for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.
The pharmacological mechanism is paradoxical: as a GnRH agonist, triptorelin initially stimulates LH and FSH release (flare effect) but with continuous exposure, causes receptor downregulation and desensitization of pituitary GnRH receptors, ultimately producing a state of chemical castration. For prostate cancer, this testosterone suppression is the therapeutic goal. Depot formulations (1-month or 3-month) maintain sustained GnRH receptor downregulation throughout treatment.
In the peptide research community, triptorelin is used very differently - as a single low dose (0.1 - 0.2 mg subcutaneously) to generate an acute LH and FSH pulse that "restarts" the HPG axis after suppression from exogenous anabolic steroids. This off-label PCT (post-cycle therapy) use exploits the initial flare effect only, administered once at the end of a cycle to stimulate endogenous testosterone recovery. This application has significant risks and should be approached with extreme caution.
The therapeutic/medical depot dosing (3.75 - 11.25 mg) is fundamentally different from the single-dose PCT approach and produces opposite hormonal outcomes. Confusing these dose regimens represents a serious medical risk.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.